San Diego genetic-sequencing pioneer Illumina is likely to face a fine of 10% of its global revenue, the maximum penalty, for closing its takeover of cancer-screening firm Grail without waiting for European Union antitrust approval.
San Diego genetic-sequencing pioneer Illumina is likely to face a fine of 10% of its global revenue, the maximum penalty, for closing its takeover of cancer-screening firm Grail without waiting for European Union antitrust approval.
This website, like most media sites, uses small files called cookies to anonymously customize the advertising that you see. Learn more about how we use cookies in our cookie policy.
